Adverse reactions associated with vaccines against COVID-19
DOI:
https://doi.org/10.21615/cesmedicina.6282Keywords:
vaccines, COVID-19, hypersensitivity, allergy, adverse reactionsAbstract
With the occurrence of the COVID-19 pandemic, the need to design strategies to help mitigate the morbimortality caused by the virus arose and one of the most promising is mass vaccination. However, vaccination may be associated with adverse reactions, including hypersensitivity reactions to the components of the different vaccines, so it is essential to know these components and the population that requires prior assessment by Allergology. Any patient who requires it should be referred in a timely manner, in order to recognize the component involved in the reaction by means of appropriate tests and to offer a course of action that allows continuing a safe vaccination schedule. This article seeks to compile data on adverse reactions, with emphasis on hypersensitivity reactions, which have occurred in clinical trials with the application of vaccines against SARS-CoV-2 to be applied in Colombia. Additionally, a proposal is made to approach patients with a history of hypersensitivity reactions with respect to the conduct that should be taken for their vaccination.
Downloads
References
Whitney CG, Zhou F, Singleton J, Schuchat A, Centers for Disease Control and Prevention (CDC). Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR Morb Mortal Wkly Rep. 2014;63(16):352–5.
Nilsson L, Brockow K, Alm J, Cardona V, Caubet J-C, Gomes E, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28(7):628–40.
Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J. 2016;9(1):32.
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44.
Martellucci CA, Flacco ME, Cappadona R, Bravi F, Mantovani L, Manzoli L. SARS-CoV-2 pandemic: An overview [Internet]. Vol. 77, Advances in Biological Regulation. 2020. p. 100736. Available from: http://dx.doi.org/10.1016/j.jbior.2020.100736
Our World in Data. Cumulative confirmes COVID-19 deaths. Global Change Data Lab. Website [Internet]. [cited 2021]. Available from: https://ourworldindata.org/grapher/cumulative-covid-deaths-region?tab=chart&stackMode=absolute&time=2020-01-11..latest®ion=World
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.
Ball P. The lightning-fast quest for COVID vaccines — and what it means for other diseases [Internet]. Vol. 589, Nature. 2021. p. 16–8. Available from: http://dx.doi.org/10.1038/d41586-020-03626-1
Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2):100517.
Ministerio de Salud y Protección Social. Vacunación contra COVID-19. Website [Internet]. [cited 2021]. Available from: https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx
Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. Reply. N Engl J Med. 2021;384(10): e37.
WHO Drug and Therapeutics Committee Training Course. Assessing and Managing Medicine Safety [Internet]. Website [Internet]. [cited 2021]. Available from: https://www.who.int/medicines/technical_briefing/tbs/04-PG_Dug-Safety_final-08.pdf?ua=1
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–93.
U.S. National Library of Medicine. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE). Website [Internet]. [cited 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT04505722
Browne SK, Beeler JA, Roberts JN. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants [Internet]. Vol. 38, Vaccine. 2020. p. 101–6. Available from: http://dx.doi.org/10.1016/j.vaccine.2019.10.048
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472.
Cardona V, Álvarez-Perea A, Ansotegui-Zubeldia IJ, Arias-Cruz A, Ivancevich JC, González-Díaz SN, et al. [Clinical Practice Guide for Anaphylaxis in Latin America (Galaxia-Latam)]. Rev Alerg Mex. 2019;66 Suppl 2:1–39.
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Website [Internet]. [cited 2021]. Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
Ministerio de Salud y Protección Social. Lineamientos técnicos y operativos para la vacunaci´n contra el COVID-19. [Internet]. [cited 2021]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/lineamientos-tecnicos-operativos-covid19-anexos.pdf
Nucera E, Aruanno A, Rizzi A, Centrone M. Latex Allergy: Current Status and Future Perspectives. J Asthma Allergy. 2020;13:385–98.
Jimenez-Rodriguez TW, Garcia-Neuer M, Alenazy LA, Castells M. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. J Asthma Allergy. 2018;11:121–42.
Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2021;126(3):e106–8.
Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract. 2021;9(4):1423–37.
Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533–40.e8.
Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy [Internet]. 2021; Available from: http://dx.doi.org/10.1111/all.14739
Sellaturay P, Nasser S, Ewan P. Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 2021;9(2):670–5.
Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. The Journal of Allergy and Clinical Immunology: In Practice [Internet]. 2021; Available from: http://dx.doi.org/10.1016/j.jaip.2021.06.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 CES Medicina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Derechos de reproducción (copyright)
Cada manuscrito se acompañará de una declaración en la que se especifique que los materiales son inéditos, que no han sido publicados anteriormente en formato impreso o electrónico y que no se presentarán a ningún otro medio antes de conocer la decisión de la revista. En todo caso, cualquier publicación anterior, sea en forma impresa o electrónica, deberá darse a conocer a la redacción por escrito.
Plagios, duplicaciones totales o parciales, traduccones del original a otro idioma son de responsabilidad exclusiva de los autores el envío.
Los autores adjuntarán una declaración firmada indicando que, si el manuscrito se acepta para su publicación, los derechos de reproducción son propiedad exclusiva de la Revista CES Medicina.
Se solicita a los autores que proporcionen la información completa acerca de cualquier beca o subvención recibida de una entidad comercial u otro grupo con intereses privados, u otro organismo, para costear parcial o totalmente el trabajo en que se basa el artículo.
Los autores tienen la responsabilidad de obtener los permisos necesarios para reproducir cualquier material protegido por derechos de reproducción. El manuscrito se acompañará de la carta original que otorgue ese permiso y en ella debe especificarse con exactitud el número del cuadro o figura o el texto exacto que se citará y cómo se usará, así como la referencia bibliográfica completa.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
